Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol

Olga B Baltzersen, Herbert Y Meltzer, Vibe G Frokjaer, Jayachandra M Raghava, Lone Baandrup, Birgitte Fagerlund, Henrik B W Larsson, H Christian Fibiger, Birte Y Glenthøj, Gitte M Knudsen, Bjørn H Ebdrup, Olga B Baltzersen, Herbert Y Meltzer, Vibe G Frokjaer, Jayachandra M Raghava, Lone Baandrup, Birgitte Fagerlund, Henrik B W Larsson, H Christian Fibiger, Birte Y Glenthøj, Gitte M Knudsen, Bjørn H Ebdrup

Abstract

Background: All current approved antipsychotic drugs against schizophrenia spectrum disorders share affinity for the dopamine receptor (D2R). However, up to one-third of these patients respond insufficiently, and in some cases, side-effects outweigh symptom reduction. Previous data have suggested that a subgroup of antipsychotic-naïve patients will respond to serotonin 2A receptor (2AR) blockade.

Aims: This investigator-initiated, translational, proof-of-concept study has overall two aims; 1) To test the clinical effectiveness of monotherapy with the newly approved drug against Parkinson's disease psychosis, pimavanserin, in antipsychotic-free patients with first-episode schizophrenia spectrum disorders; 2) To characterize the neurobiological profile of responders to pimavaserin.

Materials and equipment: Forty patients will be enrolled in this 6-week open label, one-armed trial with the selective serotonin 2AR antagonist (pimavanserin 34 mg/day). At baseline, patients will undergo: positron emission tomography (PET) imaging of the serotonin 2AR using the radioligand [¹¹C]Cimbi-36; structural magnetic resonance imaging (MRI); MR spectroscopy of cerebral glutamate levels and diffusion tensor imaging; cognitive and psychopathological examinations; electrocardiogram, and blood sampling for genetic- and metabolic analyses.

Outcome measures: The primary clinical endpoint will be reduction in the Positive and Negative Syndrome Scale (PANSS) positive score. Secondary clinical endpoints comprise multiple clinical ratings (positive and negative symptoms, depressive-, obsessive-compulsive symptoms, quality of life, social functioning, sexual functioning, and side-effects). PET, MRI, and cognitive parameters will be used for in-depth neuropsychiatric characterization of pimavanserin response.

Anticipated results: Clinically, we expect pimavanserin to reduce psychotic symptoms with similar effect as observed with conventional antipsychotics, for which we have comparable historical data. We expect pimavanserin to induce minimal side-effects. Neurobiologically, we expect psychotic symptom reduction to be most prominent in patients with low frontal serotonin 2AR binding potential at baseline. Potential pro-cognitive and brain structural effects of pimavanserin will be explored.

Perspectives: Sub-Sero will provide unique information about the role serotonin 2AR in antipsychotic-free, first-episode psychosis. If successful, Sub-Sero will aid identification of a "serotonergic subtype" of schizophrenia spectrum patients, thereby promoting development of precision medicine in clinical psychiatry.

Clinical trial registration: ClinicalTrials, identifier NCT03994965.

Keywords: Pimavanserin; antipsychotic-free; cognition; first-episode schizophrenia spectrum patients; magnetic resonance imaging; psychopathology; serotonin 2A receptor positron emission tomography; side-effects.

Copyright © 2020 Baltzersen, Meltzer, Frokjaer, Raghava, Baandrup, Fagerlund, Larsson, Fibiger, Glenthøj, Knudsen and Ebdrup.

Figures

Figure 1
Figure 1
Treatment response, amisulpride. Historical data from our group showing changes in PANSS positive symptoms in an independent cohort of 46 antipsychotic-naïve, first-episode schizophrenia patients treated with amisulpride (mean dose of 279.4 mg/day) monotherapy for six weeks. Details on the cohort have previously been published, e.g.(Nielsen et al., 2012a; Nielsen et al., 2012b; Nielsen et al., 2016; Wulff et al., 2019).

References

    1. Abbas A. I., Hedlund P. B., Huang X.-P., Tran T. B., Meltzer H. Y., Roth B. L. (2009). Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacol. (Berl) 205 (1), 119–128. 10.1007/s00213-009-1521-8
    1. Addington D., Addington J., Maticka-Tyndale E. (1993). Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry Suppl. (22), 39–44. 10.1192/S0007125000292581
    1. Bak N., Ebdrup B. H. H., Oranje B., Fagerlund B., Jensen M. H. H., Düring S. W. W., et al. (2017). Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology. Transl. Psychiatry 7 (4), e1087. 10.1038/tp.2017.59
    1. Ballard C., Banister C., Khan Z., Cummings J., Demos G., Coate B., et al. (2018). Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 17 (3), 213–222. 10.1016/S1474-4422(18)30039-5
    1. Bejerot S., Edman G., Anckarsater H., Berglund G., Gillberg C., Hofvander B., et al. (2014). The Brief Obsessive-Compulsive Scale (BOCS): a self-report scale for OCD and obsessive-compulsive related disorders. Nord. J. Psychiatry 68 (8), 549–559. 10.3109/08039488.2014.884631
    1. Carlsson A. (1977). Does dopamine play a role in schizophrenia? Psychol. Med. 7 (4), 583–597. 10.1017/s003329170000622x
    1. Clayton A. H., McGarvey E. L., Clavet G. J. (1997). The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol. Bull. 33 (4), 731–745.
    1. Coello K., Broberg B. V., Bak N., Madsen A., Mortensen H. B., Søgaard B., et al. (2015). Postprandial prolactin suppression appears absent in antipsychotic-treated male patients. Psychoneuroendocrinology 60, 1–6. 10.1016/j.psyneuen.2015.05.014
    1. Ebdrup B. H., Nørbak H., Borgwardt S., Glenthøj B. (2013). Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review. Curr. Med. Chem. 20 (3), 438–447. 10.2174/0929867311320030015
    1. Ebdrup B. H., Knop F. K., Madsen A., Mortensen H. B., Søgaard B., Holst J. J., et al. (2014). Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients. J. Clin. Psychiatry 75 (9), e899–e905. 10.4088/JCP.13m08820
    1. Ettrup A., Da Cunha-Bang S., Mcmahon B., Lehel S., Dyssegaard A., Skibsted A. W., et al. (2014). Serotonin 2A receptor agonist binding in the human brain with [11 C]Cimbi-36. J. Cereb. Blood Flow Metab. 34 (7), 1188–1196. 10.1038/jcbfm.2014.68
    1. Fda (2017). Full prescribing information. Nuplazid, 1–15.
    1. Gardell L. R., Vanover K. E., Pounds L., Johnson R. W., Barido R., Anderson G. T., et al. (2007). ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models. J. Pharmacol. Exp. Ther. 322 (2), 862–870. 10.1124/jpet.107.121715
    1. Geyer M. A., Vollenweider F. X. (2008). Serotonin research: contributions to understanding psychoses. Trends Pharmacol. Sci. 29 (9), 445–453. 10.1016/j.tips.2008.06.006
    1. Heinrichs D. W., Hanlon T. E., Carpenter W. T. J. (1984). The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 10 (3), 388–398. 10.1093/schbul/10.3.388
    1. Hjorthoj C. R., Vesterager L., Nordentoft M. (2013). Test-retest reliability of the Danish Adult Reading Test in patients with comorbid psychosis and cannabis-use disorder. Nord. J. Psychiatry 67 (3), 159–163. 10.3109/08039488.2012.691544
    1. Howes O. D., Kapur S. (2009). The Dopamine Hypothesis of Schizophrenia: Version III–The Final Common Pathway. Schizophr. Bull. 35 (3), 549–562. 10.1093/schbul/sbp006
    1. Kahn R. S., Winter van Rossum I., Leucht S., McGuire P., Lewis S. W., Leboyer M., et al. (2018). Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry 5 (10), 797–807. 10.1016/S2215-0366(18)30252-9
    1. Kaur G., Gupta D., Chavan B. S., Sinhmar V., Prasad R., Tripathi A., et al. (2017). Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India. Asian J. Psychiatr. 29, 174–182. 10.1016/j.ajp.2017.07.026
    1. Kay S. R., Opler L. A., Lindenmayer J. P. (1989). The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br. J. Psychiatry Suppl. (7), 59–67. 10.1192/S0007125000291514
    1. Kirkpatrick B., Strauss G. P., Nguyen L., Fischer B. A., Daniel D. G., Cienfuegos A., et al. (2011). The brief negative symptom scale: psychometric properties. Schizophr. Bull. 37 (2), 300–305. 10.1093/schbul/sbq059
    1. Knudsen G. M., Jensen P. S., Erritzoe D., Baaré W. F. C., Ettrup A., Fisher P. M., et al. (2016). The Center for Integrated Molecular Brain Imaging (Cimbi) database. Neuroimage. 124, 1213–1219. 10.1016/j.neuroimage.2015.04.025
    1. Kreutzer J. S., DeLuca J., Caplan B. (Eds.) (2011). “WAIS-IV,” in Encyclopedia of Clinical Neuropsychology (New York, NY: Springer New York;), 2667.
    1. Meltzer H., Massey B. (2011). The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr. Opin. Pharmacol. 11 (1), 59–67. 10.1016/j.coph.2011.02.007
    1. Meltzer H. Y., Arvanitis L., Bauer D., Rein W. (2004). Meta-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry 161 (6), 975–984. 10.1176/appi.ajp.161.6.975
    1. Meltzer H. Y., Elkis H., Vanover K., Weiner D. M., van Kammen D. P., Peters P., et al. (2012). Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day. Schizophr. Res. 141 (2–3), 144–152. 10.1016/j.schres.2012.07.029
    1. Meltzer H. Y. (2013). Update on typical and atypical antipsychotic drugs. Annu. Rev. Med. 64 (1), 393–406. 10.1146/annurev-med-050911-161504
    1. Morosini P. L., Magliano L., Brambilla L., Ugolini S., Pioli R. (2000). Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. 101 (4), 323–329. 10.1034/j.1600-0447.2000.101004323.x
    1. Nørbak-Emig H., Ebdrup B. H., Fagerlund B., Svarer C., Rasmussen H., Friberg L., et al. (2016). Frontal D 2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology. Int. J. Neuropsychopharmacol. 19 (5), pyw006. 10.1093/ijnp/pyw006
    1. Naber D., Moritz S., Lambert M., Pajonk F. G., Holzbach R., Mass R., et al. (2001). Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr. Res. 50 (1–2), 79–88. 10.1016/S0920-9964(00)00166-3
    1. Nasrallah H. A., Fedora R., Morton R. (2019). Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin , a serotonin 5HT-2A receptor inverse agonist. Schizophr. Res. (208), 10–13. 10.1016/j.schres.2019.02.018
    1. Nelson H. E. (1982). National Adult Reading Test (NART): For the assessment of premorbid intelligence in patients with dementia: Test manual. Nfer-Nelson 1–25.
    1. Nielsen MØ, Rostrup E., Wulff S., Bak N., Lublin H., Kapur S., et al. (2012. a). Alterations of the brain reward system in antipsychotic naïve schizophrenia patients. Biol. Psychiatry 71 (10), 898–905. 10.1016/j.biopsych.2012.02.007
    1. Nielsen M. O., Rostrup E., Wulff S., Bak N., Broberg B. V., Lublin H., et al. (2012. b). Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch. Gen. Psychiatry 69, 12, 1195–1204. 10.1001/archgenpsychiatry.2012.847
    1. Nielsen MØ, Rostrup E., Wulff S., Glenthøj B., Ebdrup B. H. (2016). Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment. JAMA Psychiatry 73 (2), 121–128. 10.1001/jamapsychiatry.2015.2582
    1. Nordentoft M., Wahlbeck K., Hällgren J., Westman J., Ösby U., Alinaghizadeh H., et al. (2013). Excess Mortality, Causes of Death and Life Expectancy in 270,770 Patients with Recent Onset of Mental Disorders in Denmark, Finland and Sweden. Burne T, editor. PloS One 8 (1), e55176. 10.1371/journal.pone.0055176
    1. Oldfield R. C. (1971). The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 9 (1), 97–113. 10.1016/0028-3932(71)90067-4
    1. Rasmussen H., Erritzoe D., Andersen R., Ebdrup B. H., Aggernaes B., Oranje B., et al. (2010). Decreased Frontal Serotonin2A Receptor Binding in Antipsychotic-Naive Patients With First-Episode Schizophrenia. Arch. Gen. Psychiatry 67 (1), 9. 10.1001/archgenpsychiatry.2009.176
    1. Rasmussen H., Ebdrup B. H., Erritzoe D., Aggernaes B., Oranje B., Kalbitzer J., et al. (2011). Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacol. (Berl) 213 (2–3), 583–592. 10.1007/s00213-010-1941-5
    1. Rasmussen H., Frokjaer V. G., Hilker R. W., Madsen J., Anhøj S., Oranje B., et al. (2016). Low frontal serotonin 2A receptor binding is a state marker for schizophrenia? Eur. Neuropsychopharmacol. 26 (7), 1248–1250. 10.1016/j.euroneuro.2016.04.008
    1. Robbins T. W., James M., Owen A. M., Sahakian B. J., McInnes L., Rabbitt P. (1994). Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 5 (5), 266–281. 10.1159/000106735
    1. Robinson D. G., Woerner M. G., Delman H. M., Kane J. M. (2005). Pharmacological Treatments for First-Episode Schizophrenia. Schizophr. Bull. 31, 3, 705–722. 10.1093/schbul/sbi032
    1. Serretti A., Drago A., De Ronchi D. (2007). HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr. Med. Chem. 14 (19), 2053–2069. 10.2174/092986707781368450
    1. Steward L. J., Kennedy M. D., Morris B. J., Pratt J. A. (2004). The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptors. Neuropharmacology 47 (4), 527–537. 10.1016/j.neuropharm.2004.04.020
    1. Vanover K. E., Robbins-Weilert D., Wilbraham D. G., Mant T. G. K., Van Kammen D. P., Davis R. E., et al. (2007). Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers. J. Clin. Pharmacol. 47 (6), 704–714. 10.1177/0091270007299431
    1. Wing J. K., Babor T., Brugha T., Burke J., Cooper J. E., Giel R., et al. (1990). SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch. Gen. Psychiatry 47 (6), 589–593. 10.1001/archpsyc.1990.01810180089012
    1. Woolley D. W., Shaw E. (1954). Some neurophysiological aspects of serotonin. Br. Med. J. 2 (4880), 122–126. 10.1136/bmj.2.4880.122
    1. Wulff S., Nielsen MØ, Rostrup E., Svarer C., Jensen L. T., Pinborg L., et al. (2019). The relation between dopamine D2 receptor blockade and the brain reward system: a longitudinal study of first-episode schizophrenia patients. Psychol. Med. 50, 1–9. 10.1017/S0033291718004099

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться